Ignite Creation Date:
2024-05-06 @ 8:10 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06287944
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-01
First Post:
2024-02-16
Brief Title:
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Sponsor:
City of Hope Medical Center
Organization:
City of Hope Medical Center
Organization Data
Organization:
City of Hope Medical Center
Class:
OTHER
Study ID:
23694
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
City of Hope Medical Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| National Cancer Institute NCI | NIH |